What is VivoSense?
Since its inception in 2010, VivoSense has been at the forefront of innovation in the pharmaceutical clinical trial industry. The company leverages its proprietary VivoSense® software to analyze and interpret data from wearable sensors, developing novel digital biomarkers. This platform is crucial for delivering real-world digital clinical measures, thereby accelerating patient-focused drug development and enabling precision medicine across various therapeutic indications such as cancer, Alzheimer's, and rare diseases. VivoSense's solutions are designed for rigorous interpretation of subtle physiological shifts, utilizing customized monitoring and analysis rooted in scientific foundations to bring life-saving treatments to patients more efficiently.
How much funding has VivoSense raised?
VivoSense has raised a total of $25.1M across 2 funding rounds:
Debt
$150K
Series A
$25M
Debt (2020): $150K with participation from PPP
Series A (2022): $25M led by Debiopharm and Perceptive Xontogeny Venture Fund
Key Investors in VivoSense
Debiopharm
Debiopharm Investment, the investment arm of Debiopharm Group, focuses on safeguarding capital and generating financial returns, suggesting a strategic interest in companies that align with the group's broader healthcare and pharmaceutical objectives.
Perceptive Xontogeny Venture Fund
Perceptive Xontogeny Venture Fund likely specializes in venture capital investments, particularly within the healthcare and life sciences sectors, aiming to support innovative companies with high growth potential.
PPP
Public-Private Partnership
What's next for VivoSense?
With the recent major strategic investment and substantial overall funding, VivoSense is poised for significant expansion. The company's focus on leveraging real-world data at scale for regulatory and medical decision-making suggests a strategic push towards broader adoption of its digital biomarker platform within the pharmaceutical sector. Future developments are likely to center on enhancing the capabilities of the VivoSense® software, expanding its application to new therapeutic areas, and forging deeper partnerships within the clinical research and drug development ecosystem. This strategic financing will empower VivoSense to further its mission of realizing the potential of novel technologies in patient care.
See full VivoSense company page
